Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab plus pomalidomide in alternating schedule for relapsed/refractory multiple myeloma
2025-522114-23-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Sep 2026
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of teclistamab and pomalidomide in multiple myeloma (MM), sponsored by University Hospital Odense. Primary endpoint: Progression-free survival at 12 months. Planned start Sep 2026; status: authorised.
02
Drugs
teclistamabpomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-522114-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522114-23-00.